- 首页
- RSV (Respiratory syncytial virus)
- Enzaplatovir
Enzaplatovir
Enzaplatovir (BTA-C585) 是一种口服有效的融合 (fusion) 抑制剂，有潜力用于呼吸道合胞病毒 (RSV) 感染的研究。
此产品仅用于科学研究，我们不为任何个人用途提供产品和服务
-
包装价格促销价数量
-
5mg￥7012.005610.00- +
-
10mg￥11337.009070.00- +
已选
0
种
0
瓶
金额:
￥0.00
首页
收藏
- 货号: ajcx34736
- CAS: 1323077-89-9
- 别名: BTA-C585
- 分子式: C20H19N5O3
- 分子量: 377.4
- 纯度: ＞98%
- 溶解度: DMSO : 200 mg/mL (529.94 mM; Need ultrasonic)
- 储存: Store at -20°C
- 库存: 现货
Background
Enzaplatovir (BTA-C585) is an orally bioavailable fusion inhibitor for respiratory syncytial virus (RSV) infection[1].
Respiratory syncytial virus (RSV)-associated lower respiratory tract infection (LRTI) imposes a substantial medical burden. Enzaplatovir is a small-molecule RSV entry inhibitor[1].
[1]. Eric A F Sim?es, et al. Past, Present and Future Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children. Infect Dis Ther. 2018 Mar;7(1):87-120.
